Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissionsoup.com..
Background: Recent data suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reductions in endometrial cancer risk, yet very few have examined whether their use is related to prognosis among endometrial cancer patients.
Methods: Study subjects comprised 4374 participants of the NRG Oncology/Gynecology Oncology Group 210 Study with endometrial carcinoma who completed a presurgical questionnaire that assessed history of regular prediagnostic NSAID use and endometrial cancer risk factors. Recurrences, vital status, and causes of death were obtained from medical records and cancer registries. Fine-Gray semiproportional hazards regression estimated adjusted subhazard ratios (HRs) and 95% confidence intervals (CIs) for associations of NSAID use with endometrial carcinoma-specific mortality and recurrence. Models were stratified by endometrial carcinoma type (ie, type I [endometrioid] vs type II [serous, clear cell, or carcinosarcoma]) and histology.
Results: Five hundred fifty endometrial carcinoma-specific deaths and 737 recurrences occurred during a median of five years of follow-up. NSAID use was associated with 66% (HR = 1.66, 95% CI = 1.21 to 2.30) increased endometrial carcinoma-specific mortality among women with type I cancers. Associations were statistically significant for former and current users, and strongest among former users who used NSAIDs for 10 years or longer (HR = 2.23, 95% CI = 1.19 to 4.18, two-sided P trend = .01). NSAID use was not associated with recurrence or endometrial carcinoma-specific mortality among women with type II tumors.
Conclusions: In this study, use of NSAIDs was associated with increased endometrial carcinoma-specific mortality, especially in patients with type I tumors. Barring a clear biologic mechanism by which NSAIDs would increase the risk of cause-specific mortality, cautious interpretation is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Journal of the National Cancer Institute - 109(2017), 3 vom: 01. März, Seite 1-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brasky, Theodore M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.07.2017 Date Revised 27.02.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jnci/djw251 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM270641939 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM270641939 | ||
| 003 | DE-627 | ||
| 005 | 20231224231010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jnci/djw251 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0902.xml |
| 035 | |a (DE-627)NLM270641939 | ||
| 035 | |a (NLM)28376204 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brasky, Theodore M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2017 | ||
| 500 | |a Date Revised 27.02.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a Background: Recent data suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reductions in endometrial cancer risk, yet very few have examined whether their use is related to prognosis among endometrial cancer patients | ||
| 520 | |a Methods: Study subjects comprised 4374 participants of the NRG Oncology/Gynecology Oncology Group 210 Study with endometrial carcinoma who completed a presurgical questionnaire that assessed history of regular prediagnostic NSAID use and endometrial cancer risk factors. Recurrences, vital status, and causes of death were obtained from medical records and cancer registries. Fine-Gray semiproportional hazards regression estimated adjusted subhazard ratios (HRs) and 95% confidence intervals (CIs) for associations of NSAID use with endometrial carcinoma-specific mortality and recurrence. Models were stratified by endometrial carcinoma type (ie, type I [endometrioid] vs type II [serous, clear cell, or carcinosarcoma]) and histology | ||
| 520 | |a Results: Five hundred fifty endometrial carcinoma-specific deaths and 737 recurrences occurred during a median of five years of follow-up. NSAID use was associated with 66% (HR = 1.66, 95% CI = 1.21 to 2.30) increased endometrial carcinoma-specific mortality among women with type I cancers. Associations were statistically significant for former and current users, and strongest among former users who used NSAIDs for 10 years or longer (HR = 2.23, 95% CI = 1.19 to 4.18, two-sided P trend = .01). NSAID use was not associated with recurrence or endometrial carcinoma-specific mortality among women with type II tumors | ||
| 520 | |a Conclusions: In this study, use of NSAIDs was associated with increased endometrial carcinoma-specific mortality, especially in patients with type I tumors. Barring a clear biologic mechanism by which NSAIDs would increase the risk of cause-specific mortality, cautious interpretation is warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 700 | 1 | |a Felix, Ashley S |e verfasserin |4 aut | |
| 700 | 1 | |a Cohn, David E |e verfasserin |4 aut | |
| 700 | 1 | |a McMeekin, D Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Mutch, David G |e verfasserin |4 aut | |
| 700 | 1 | |a Creasman, William T |e verfasserin |4 aut | |
| 700 | 1 | |a Thaker, Premal H |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Joan L |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Richard G |e verfasserin |4 aut | |
| 700 | 1 | |a Lele, Shashikant B |e verfasserin |4 aut | |
| 700 | 1 | |a Guntupalli, Saketh R |e verfasserin |4 aut | |
| 700 | 1 | |a Downs, Levi S |e verfasserin |4 aut | |
| 700 | 1 | |a Nagel, Christa I |e verfasserin |4 aut | |
| 700 | 1 | |a Boggess, John F |e verfasserin |4 aut | |
| 700 | 1 | |a Pearl, Michael L |e verfasserin |4 aut | |
| 700 | 1 | |a Ioffe, Olga B |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Kay J |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Shamshad |e verfasserin |4 aut | |
| 700 | 1 | |a Brinton, Louise A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Cancer Institute |d 1945 |g 109(2017), 3 vom: 01. März, Seite 1-10 |w (DE-627)NLM000019747 |x 1460-2105 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2017 |g number:3 |g day:01 |g month:03 |g pages:1-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jnci/djw251 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2017 |e 3 |b 01 |c 03 |h 1-10 | ||